Michael
Dentistry
Nobel Bio-care
Sweden
Biography
He founded Synovo GmbH in Tubingen, Germany in 2004, and has since added 4 other self-sustaining enterprises. Synovo is a drug discovery and services company with a focus on in vivo disease models. In 2008, Synovo discovered a novel series of potent micro-environment modulators that modulate the cytokine patterns of tumours and notably that of the myeloid infiltrate. These substances synergize both checkpoint and other antibody therapies. The series has since received orphan designation for pancreas cancer. Michael’s research focus is mechanisms of improved immunotherapy in oncology.
Research Interest
Dentistry
